RxDoctor Payments Data

Hans Andreasen, MD

Family Medicine · Terre Haute, INNPI 1811002587

Payments from drug & device makers

$548in general payments, 2019–2025

Across 33 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$166
  • Dexcom, Inc.$123
  • GSK$86
  • AbbVie$72
  • Johnson & Johnson$29
  • Pfizer$23
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$52896%
  • Education$204%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk10$166
Dexcom, Inc.6$123
GSK5$86
AbbVie(2 entities)5$72
Johnson & Johnson2$29
Pfizer2$23
E.r. Squibb & Sons, L.L.C.1$20
Lilly USA, LLC1$15
Amgen1$13

How this compares

$548 in reported general payments places this provider in the 50th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$82,702
Medicare patients
239
Services billed
988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate130$107,444
OzempicSemaglutide87$83,679
JardianceEmpagliflozin68$62,904
EliquisApixaban60$48,546
MounjaroTirzepatide42$43,909
RelistorMethylnaltrexone Bromide17$28,397
Combivent RespimatIpratropium/Albuterol Sulfate32$18,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,278
SymbicortBudesonide/Formoterol Fumarate28$8,786
Breo ElliptaFluticasone/Vilanterol19$6,971
AbrysvoRsv Vacc, Pref A And Pref B/Pf23$6,487
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$6,368
ShingrixVaricella-Zoster Ge/As01b/Pf25$4,754
Memantine Hcl ErMemantine Hcl32$3,897
Atorvastatin Calcium446$3,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$166$83,67987 claims
PfizerEliquis, Abrysvo$23$55,03283 claims
Lilly USA, LLCMounjaro$15$43,90942 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$86$21,00356 claims
AbbVieSynthroid$72$2,69947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →